Key result
Beta-blockers evaluated for progression-free and overall survival in glioblastoma patients with cardiovascular disease.
Why the study?
Does beta-blocker use improve progression free survival and overall survival in glioblastoma patients with cardiovascular disease?
Does beta-blocker use improve progression free survival and overall survival in glioblastoma patients with cardiovascular disease?
Beta-blocker use may be associated with PFS benefit in glioblastoma; hypothesis-generating and should not change practice.
We investigated whether the use of beta-blockers (BB) for cardiovascular disease (CVD) yields progression free survival (PFS) and overall survival (OS) benefit in glioblastoma (GBM) patients.
No takes yet. Share an insight, caveat, or question.
Hanlon et al. (2026) studied this question. Beta-blocker administration for cardiovascular disease was evaluated for potential progression-free and overall survival benefits in patients with glioblastoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: